$0.99-0.03 (-2.94%)
Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States.
Invivyd, Inc. in the Healthcare sector is trading at $0.99 with a market capitalization of $324M. Wall Street consensus targets $10.00 (3 analysts), implying a +910.1% move over the next 12 months. The stock is currently near its 52-week low of $0.48, remaining 41.8% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, ...
Invivyd Inc (NASDAQ:IVVD) has dosed the first participants in its LIBERTY Phase 3 trial, a study testing the company's monoclonal antibody VYD2311 for the prevention of COVID-19 against and alongside an mRNA vaccine. The randomized, double-blind trial is evaluating the safety, tolerability...
Invivyd (IVVD) dosed the first participants in the LIBERTY phase 3 clinical trial evaluating the saf
Looking at Invivyd, Inc.'s ( NASDAQ:IVVD ) insider transactions over the last year, we can see that insiders were net...
Invivyd Inc. (NASDAQ:IVVD) is one of the best NASDAQ stocks under $5 to buy right now. On May 14, Invivyd reported earnings for Q1 2026, highlighted by $13.7 million in PEMGARDA net product revenue, which marks a 22% growth compared to Q1 2025. The company ended the quarter with $184.2 million in cash and cash […]
Invivyd Inc (IVVD) reports robust monoclonal antibody revenue growth and strategic clinical investments, while navigating challenges in public education and regulatory uncertainties.